Thursday, May 9, 2013
Publication and contact
Colorectal cancer (CRC)
classification system that correlates cellular phenotype to clinical outcome
Computational analysis of
drug-induced gene expression profiles in CRC provides a classification system
that could be used to guide treatment decisions. Gene expression data from
1,290 CRC tumors were analyzed and mapped to a data set of clinical responses
to the epidermal growth factor receptor
(EGFR) inhibitor Erbitux cetuximab in 80
patients. Six subgroups were identified that corresponded to different levels
of disease-free survival. For each subgroup, gene expression and protein
biomarkers were identified that could be used to propose subtype-specific
therapeutic strategies. Next steps include refining the quantitative gene
expression approach and further validating the CRC subtype-specific
signatures using additional retrospective sample sets.
Eli Lilly and Co. and
partners Bristol-Myers Squibb Co.
and Merck KGaA market Erbitux
to treat CRC and head and neck cancer.
Published online May 9, 2013
Patent status undisclosed;
available for licensing
Sadanandam, A. et al.
Nat. Med.; published online April 14, 2013;
Contact: Douglas Hanahan, Swiss Institute of Bioinformatics,
Contact: Joe W. Gray, Oregon
Health & Science University,
All contents Copyright © 1993-2017 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]